Autolus Therapeutics (NASDAQ:AUTL) Hits New 12-Month Low – Time to Sell?

Autolus Therapeutics plc (NASDAQ:AUTL) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $2.07 and last traded at $2.14, with a volume of 322885 shares changing hands. The stock had previously closed at $2.11.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on AUTL shares. Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a report on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, January 13th. Finally, The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $10.40.

Autolus Therapeutics Price Performance

The firm’s fifty day moving average is $2.51 and its 200 day moving average is $3.42. The firm has a market capitalization of $578.75 million, a price-to-earnings ratio of -1.80 and a beta of 2.02.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period last year, the company posted ($0.26) earnings per share. Equities research analysts forecast that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of AUTL. Wellington Management Group LLP lifted its stake in Autolus Therapeutics by 35.4% in the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after acquiring an additional 6,330,392 shares in the last quarter. FMR LLC lifted its stake in shares of Autolus Therapeutics by 44.6% in the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after acquiring an additional 5,478,706 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Autolus Therapeutics by 145.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company’s stock worth $4,663,000 after buying an additional 761,008 shares during the period. Millennium Management LLC raised its holdings in Autolus Therapeutics by 113.7% during the 2nd quarter. Millennium Management LLC now owns 813,031 shares of the company’s stock worth $2,829,000 after purchasing an additional 432,503 shares during the last quarter. Finally, State Street Corp grew its stake in Autolus Therapeutics by 1.7% during the third quarter. State Street Corp now owns 606,544 shares of the company’s stock worth $2,202,000 after purchasing an additional 10,401 shares during the period. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.